Mesenchymal stem cells therapy for chronic ischemic stroke-a systematic review.

IF 0.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Asian Biomedicine Pub Date : 2024-10-31 eCollection Date: 2024-10-01 DOI:10.2478/abm-2024-0027
Mohammad Kurniawan, Yetty Ramli, Nadira Deanda Putri, Salim Harris, Al Rasyid, Taufik Mesiano, Rakhmad Hidayat
{"title":"Mesenchymal stem cells therapy for chronic ischemic stroke-a systematic review.","authors":"Mohammad Kurniawan, Yetty Ramli, Nadira Deanda Putri, Salim Harris, Al Rasyid, Taufik Mesiano, Rakhmad Hidayat","doi":"10.2478/abm-2024-0027","DOIUrl":null,"url":null,"abstract":"<p><p>Stroke represents a significant global health issue, primarily in the form of ischemic stroke. Despite the availability of therapeutic interventions, the recovery from chronic stroke, occurring 3 months post-initial stroke, poses substantial challenges. A promising avenue for post-acute stroke patients is mesenchymal stem cells (MSCs) therapy, which is derived from various sources and is globally recognized as the most utilized and extensively studied stem cell therapy. This systematic review, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, aims to synthesize evidence regarding the impact of MSCs therapy on patients with chronic ischemic stroke. Employing an advanced search strategy across databases such as PubMed, PubMed Central, Google Scholar, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrial.gov, a total of 70 studies were identified, with 4studies meeting the inclusion criteria. Although positive outcomes were observed in terms of efficacy and safety, certain limitations, such as small sample sizes, study heterogeneity, and the absence of placebo groups, undermine the overall strength of the evidence. It is crucial to address these limitations in future research, highlighting the importance of larger sample sizes, standardized methodologies, and comparative trials to improve the assessment of MSCs' efficacy and safety. Moving forward, key priorities include exploring underlying mechanisms, determining optimal administration modes and dosages, and conducting comparative trials. By addressing these aspects, we can propel MSCs therapies toward greater efficacy, safety, and applicability across diverse patient populations.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524678/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Biomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/abm-2024-0027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Stroke represents a significant global health issue, primarily in the form of ischemic stroke. Despite the availability of therapeutic interventions, the recovery from chronic stroke, occurring 3 months post-initial stroke, poses substantial challenges. A promising avenue for post-acute stroke patients is mesenchymal stem cells (MSCs) therapy, which is derived from various sources and is globally recognized as the most utilized and extensively studied stem cell therapy. This systematic review, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, aims to synthesize evidence regarding the impact of MSCs therapy on patients with chronic ischemic stroke. Employing an advanced search strategy across databases such as PubMed, PubMed Central, Google Scholar, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrial.gov, a total of 70 studies were identified, with 4studies meeting the inclusion criteria. Although positive outcomes were observed in terms of efficacy and safety, certain limitations, such as small sample sizes, study heterogeneity, and the absence of placebo groups, undermine the overall strength of the evidence. It is crucial to address these limitations in future research, highlighting the importance of larger sample sizes, standardized methodologies, and comparative trials to improve the assessment of MSCs' efficacy and safety. Moving forward, key priorities include exploring underlying mechanisms, determining optimal administration modes and dosages, and conducting comparative trials. By addressing these aspects, we can propel MSCs therapies toward greater efficacy, safety, and applicability across diverse patient populations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
间充质干细胞治疗慢性缺血性中风--系统综述。
中风是一个重大的全球性健康问题,主要表现为缺血性中风。尽管有治疗干预措施,但慢性中风(发生在首次中风后 3 个月)的恢复仍面临巨大挑战。间充质干细胞(MSCs)疗法是治疗急性中风后患者的一个很有前景的途径,间充质干细胞来源广泛,是全球公认的使用最多、研究最广泛的干细胞疗法。本系统综述遵循系统综述和元分析首选报告项目(PRISMA)指南,旨在综合间充质干细胞疗法对慢性缺血性中风患者影响的相关证据。通过在 PubMed、PubMed Central、Google Scholar、Cochrane Central Register of Controlled Trials (CENTRAL) 和 ClinicalTrial.gov 等数据库中采用高级检索策略,共确定了 70 项研究,其中 4 项符合纳入标准。虽然在疗效和安全性方面观察到了积极的结果,但某些局限性,如样本量小、研究异质性和缺乏安慰剂组等,削弱了证据的整体强度。在未来的研究中,解决这些局限性至关重要,强调了更大样本量、标准化方法和比较试验对改善间充质干细胞疗效和安全性评估的重要性。今后的重点工作包括探索潜在机制、确定最佳给药模式和剂量以及开展比较试验。通过解决这些方面的问题,我们可以推动间充质干细胞疗法实现更高的疗效、安全性和对不同患者群体的适用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Asian Biomedicine
Asian Biomedicine 医学-医学:研究与实验
CiteScore
1.20
自引率
0.00%
发文量
24
审稿时长
6-12 weeks
期刊介绍: Asian Biomedicine: Research, Reviews and News (ISSN 1905-7415 print; 1875-855X online) is published in one volume (of 6 bimonthly issues) a year since 2007. [...]Asian Biomedicine is an international, general medical and biomedical journal that aims to publish original peer-reviewed contributions dealing with various topics in the biomedical and health sciences from basic experimental to clinical aspects. The work and authorship must be strongly affiliated with a country in Asia, or with specific importance and relevance to the Asian region. The Journal will publish reviews, original experimental studies, observational studies, technical and clinical (case) reports, practice guidelines, historical perspectives of Asian biomedicine, clinicopathological conferences, and commentaries Asian biomedicine is intended for a broad and international audience, primarily those in the health professions including researchers, physician practitioners, basic medical scientists, dentists, educators, administrators, those in the assistive professions, such as nurses, and the many types of allied health professionals in research and health care delivery systems including those in training.
期刊最新文献
A preliminary study of primary retroperitoneal sarcoma at a tertiary University Hospital in Bangkok, Thailand: a retrospective observational study. Mesenchymal stem cells therapy for chronic ischemic stroke-a systematic review. Preventive effects of coixol, an active compound of adlay seed, in NGF-differentiated PC12 cells against beta-amyloid25-35-induced neurotoxicity. Risk factors of cholangiocarcinoma in areas not endemic for liver fluke infection. Risk factors of cholangiocarcinoma: more than control of liver fluke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1